UnipharDUB:UPR -0.65%82 Days Payable is 84.90 as of Dec. 2025, which is 98% above its 10-year median of 42.97. GuruFocus rates DUB:UPR with a GF Score™ of 82/100 and a GF Value™ of €3.64 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 115 Medical Distribution companies, Uniphar ranks worse than 53.91% on this metric.
Uniphar's average Accounts Payable for the
six
months ended in Dec. 2025 was €629 Mil. Uniphar's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €1,351 Mil.
Hence, Uniphar's Days Payable for the
six
months ended in Dec. 2025 was 84.90.
The historical rank and industry rank for Uniphar's Days Payable or its related term are showing as below:
DUB:UPR'
s Days Payable Range Over the Past 10 Years
Min: 39.33 Med: 42.97 Max: 75.89
Current: 75.89
During the past 10 years, Uniphar's highest Days Payable was 75.89. The lowest was 39.33. And the median was 42.97.
DUB:UPR's Days Payable is ranked worse than 53.91% of 115
companies
in the Medical Distribution industry
Industry Median: 79.81
vs DUB:UPR: 75.89
Uniphar's Days Payable
increased
from Dec. 2024 (73.57) to Dec. 2025 (84.90).
It may suggest that Uniphardelayed paying its suppliers.
Uniphar Days Payable Related Terms
Uniphar Days Payable Historical Data
* Premium members only.
The historical data trend for Uniphar's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Uniphar's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's Days Payable distribution charts can be found below:
* The bar in red indicates where Uniphar's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Uniphar's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Uniphar (DUB:UPR) has a Days Payable of 84.90 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Uniphar and its competitors. This is 98% above median its historical median of 42.97. Over the past decade, Uniphar's Days Payable has ranged from 39.33 to 75.89. According to the industry distribution chart, Uniphar ranks #62 out of 115 companies in the Medical Distribution industry, placing it in the top 53.9%.
Is Uniphar's Days Payable too high?
Uniphar's current Days Payable of 84.90 is 98% above median its 10-year median of 42.97. Over the past 10 years, this metric has ranged from a low of 39.33 to a high of 75.89. The Medical Distribution industry median Days Payable is 79.81. Uniphar's value of 84.90 is 6.4% above this industry median. Based on the distribution chart, Uniphar ranks #62 out of 115 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Uniphar has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's Days Payable compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Uniphar ranks #62 out of 115 companies for Days Payable. This places Uniphar in the lower half of its industry. The industry median Days Payable is 79.81. Uniphar's value of 84.90 is 6.4% above this benchmark. Historically, Uniphar's own Days Payable has ranged from 39.33 to 75.89 over the past decade. While the company's 10-year median is 42.97 vs. the industry median of 79.81, Uniphar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.81, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current Days Payable of 84.90 is 6.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median Days Payable is 79.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current Days Payable is 84.90, which is 98% above median its own 10-year median of 42.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.57 — trading 25.5% above its estimated fair value. The current Days Payable is 84.90, which is 98% above median its 10-year median of 42.97 and 6.4% above the Medical Distribution industry median of 79.81. Uniphar's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current Days Payable is 84.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.57 is trading 25.5% above its estimated GF Value™ of €3.64.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for DUB:UPR:
Days Payable: 84.90 (98% above median its 10-year median of 42.97)
GF Value™: €3.64 vs. price of €4.57 (25.5% above fair value)
Industry Position: 6.4% above the Medical Distribution median (#62 of 115)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
82GF Score
Get the complete analysis for DUB:UPR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
